ArticleJournal of thoracic disease2026
Prognostic value of pretreatment systemic immune-inflammation index for overall survival in esophageal squamous cell carcinoma in China: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Systemic immune-inflammation index (SII) has been identified as an independent risk factor for poor prognosis in patients with esophageal squamous cell carcinoma (ESCC). However, findings reported in different studies are contradictory. This systematic review and meta-analysis aim to clarify the relationship between pre-treatment SII and long-term survival outcomes in ESCC. Methods: Systematic searches were carried out in PubMed, EMBASE, Web of Science, CNKI, Wanfang, and SinoMed from their respective inceptions up to April 13, 2026. Eligible studies enrolled patients with histologically confirmed ESCC and a clearly defined pretreatment SII cut-off, only hazard ratios (HRs) from multivariate Cox regression were extracted. Non-original articles, low-quality studies, and those lacking key data were excluded. Two reviewers independently extracted data and assessed study quality using the Newcastle-Ottawa Scale (NOS). Publication bias was evaluated with funnel plots and Egger's test. Outcomes were overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Results: Ten retrospective cohort studies (3,660 patients) were included, all conducted in China with NOS scores of 6-8. Elevated pretreatment SII was correlated with poorer OS (pooled HR =1.52, 95% CI: 1.36-1.69, P<0.001; I Conclusions: In Chinese patients with ESCC, pretreatment SII appears to be a promising prognostic biomarker in ESCC, elevated levels predict poorer OS and DFS/PFS, and are associated with more advanced clinicopathological stage. Large scale prospective studies, especially in other ethnic populations, are needed to confirm the clinical applicability of this indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.